Efficacy of high-concentration tacalcitol ointment in psoriasis vulgaris after changing from other high-concentration vitamin D3 ointments

Dermatology Online Journal

Volumn 14, Issue 2, 2008, Pages

  Abe, Masatoshi ^a   Syuto, Tomoko ^a   Ishibuchi, Hirohisa ^a   Sogabe, Yoko ^a   Yokoyama, Yoko ^a   Ishikawa, Osamu ^a  

^a GUNMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

22 OXACALCITRIOL; CALCIPOTRIOL; TACALCITOL; 1 ALPHA,24 DIHYDROXYVITAMIN D3; 1 ALPHA,24-DIHYDROXYVITAMIN D3; CALCITRIOL; DIHYDROXYCOLECALCIFEROL; DRUG DERIVATIVE;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; HUMAN; INTERVIEW; PSORIASIS VULGARIS; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG ADMINISTRATION; ECONOMICS; FEE; HOSPITALIZATION; OINTMENT; PATIENT ATTITUDE; PSORIASIS; TREATMENT OUTCOME;

CALCITRIOL; DIHYDROXYCHOLECALCIFEROLS; DRUG ADMINISTRATION SCHEDULE; HUMANS; OINTMENTS; PATIENT ACCEPTANCE OF HEALTH CARE; PRESCRIPTION FEES; PSORIASIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 41149142289     PISSN: None     EISSN: 10872108     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Matsumoto K, Hashimoto K, Kiyoki M, Yamamoto M, Yoshikawa K. Effect of 1,24R-dihydroxyvitamin D3 on the growth of human keratinocytes. J Dermatol. 1990 Feb;17(2):97.
2. Matsunaga T, Yamamoto M, Mimura H, Ohta T, Kiyoki M, Ohba T, Naruchi T, Hosoi J, akutoki T. 1,24(R)-dihydroxyvitamin D3, a novel active form of vitamin D3 with high activity for inducing epidermal differentiation but decreased hypercalcemic activity. J Dermatol. 1990 Mar;17(3):135.
3. Lambert J, Trompke C. Tacalcitol ointment for long-term control of chronic plaque psoriasis in dermatological practice. Dermatology. 2002 ;204 (4):321.
4. Van de Kerkhof PC, Berth-Jones J, Griffiths CE, Harrison PV, Hönigsmann H, Marks R, Roelandts R, Schöpf E, Trompke C. Long-term efficacy and safety of tacalcitol ointment in patients with chronic plaque psoriasis. Br J Dermatol. 2002 Mar;146(3):414.
5. Scott LJ, Dunn CJ, Goa KL. Calcipotriol ointment. A review of its use in the management of psoriasis. Am J Clin Dermatol. 2001 ;2(2):95.
6. Hardman KA, Heath DA, Nelson HM. Hypercalcaemia associated with calcipotriol (Dovonex) treatment. BMJ. 1993 Apr 3;306(6882):896.
7. Bourke JF, Iqbal SJ, Hutchinson PE. Vitamin D analogues in psoriasis: effects on systemic calcium homeostasis. Br J Dermatol. 1996 Sep;135 (3):347.
8. Kawahara C, Okada Y, Tanikawa T, Fukusima A, Misawa H, Tanaka Y. Severe hypercalcemia and hypernatremia associated with calcipotriol for treatment of psoriasis. J Bone Miner Metab. 2004 ;22(2):159.
9. Miyachi Y, Ohkawara A, Ohkido M, Harada S, Tamaki K, Nakagawa H, Hori Y, Nishiyama S. Long-term safety and efficacy of high-concentration (20 microg/g) tacalcitol ointment in psoriasis vulgaris. Eur J Dermatol. 2002 Sep-Oct;12(5):463.
10. Katayama I, Ohkawara A, Ohkido M, Harada S, Tamaki K, Nakagawa H, Hori Y, Nishiyama S. High-concentration (20 mug/g) tacalcitol ointment therapy on refractory psoriasis vulgaris with low response to topical corticosteroids. Eur J Dermatol. 2002 Nov-Dec;12(6):553.
11. Barker JN, Ashton RE, Marks R, Harris RI, Berth-Jones J. Topical maxacalcitol for the treatment of psoriasis vulgaris: a placebo-controlled, double-blind, dose-finding study with active comparator. Br J Dermatol. 1999 Aug;141(2):274.
12. J Sugai. Proceedings of the 18th annual meeting of the Japanese society for psoriasis research (in Japanese).